Zhang, Huilai

AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma

Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G. S., et al. (2019) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 434

Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas

Bi, C., Zhang, X., Lu, T., Zhang, X., Wang, X., Meng, B., Zhang, H., Wang, P., Vose, J. M., Chan, W. C., et al. (2017) · Haematologica

PI3K/AKT/mTOR signaling in cancerLymphoma Diagnosis and Treatment

Cited by 32

p53: from understanding its structure to advances in therapeutic targeting

Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 30